PUBLISHER: The Business Research Company | PRODUCT CODE: 2036079
PUBLISHER: The Business Research Company | PRODUCT CODE: 2036079
Recurrent implantation failure panels are comprehensive diagnostic test sets used in reproductive medicine to investigate repeated failures of embryo implantation following assisted reproductive techniques like IVF. These panels typically include assessments of genetic, immunological, hormonal, thrombophilia, and uterine receptivity factors to identify potential barriers to successful implantation.
The key product types of recurrent implantation failure panels include genetic panels, immunological panels, endometrial receptivity panels, combined panels, and other variants. Genetic panels assess genetic factors contributing to implantation failure. Technologies include polymerase chain reaction (PCR), next-generation sequencing, microarray, immunoassay, and others. Sample types include blood, tissue, and others, serving hospitals, clinics, diagnostic laboratories, fertility centers, and other end-users.
Tariffs have influenced the recurrent implantation failure panels market by increasing import costs for advanced genetic, immunological, and endometrial testing equipment and reagents. This has primarily affected genetic panels and next-generation sequencing technologies, especially in regions like North America and Europe that rely on imported high-precision instruments. In response, manufacturers are focusing on local production, diversifying supply chains, and innovating cost-effective solutions, which could enhance accessibility and promote market growth.
The recurrent implantation failure panels market research report is one of a series of new reports from The Business Research Company that provides recurrent implantation failure panels market statistics, including recurrent implantation failure panels industry global market size, regional shares, competitors with a recurrent implantation failure panels market share, detailed recurrent implantation failure panels market segments, market trends and opportunities, and any further data you may need to thrive in the recurrent implantation failure panels industry. This recurrent implantation failure panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The recurrent implantation failure panels market size has grown strongly in recent years. It will grow from $0.82 billion in 2025 to $0.9 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising infertility awareness, adoption of conventional IVF protocols, growth of diagnostic laboratories, increasing use of genetic testing, demand for endometrial evaluation.
The recurrent implantation failure panels market size is expected to see strong growth in the next few years. It will grow to $1.31 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to integration of ai and machine learning, expansion of fertility clinics, adoption of multi-omics approaches, development of automated testing platforms, increasing patient demand for personalized fertility solutions. Major trends in the forecast period include personalized implantation risk assessment, integration of multi-omics data, ai-based predictive fertility modeling, real-time monitoring of endometrial receptivity, automation in genetic and immunological testing.
The rising prevalence of infertility globally is anticipated to propel the growth of the recurrent implantation failure (RIF) panels market during the forecast period. Infertility refers to the inability to conceive after 12 months of regular, unprotected sexual intercourse. Increasing infertility rates are primarily driven by factors such as delayed childbearing, lifestyle modifications, and age-related declines in reproductive capacity, which elevate the risk of conception difficulties and unsuccessful assisted reproductive outcomes. Recurrent implantation failure panels aid infertility management by detecting genetic, immunological, and hormonal factors that may obstruct successful embryo implantation, allowing clinicians to develop more personalized treatment plans and enhance in vitro fertilization (IVF) success rates. For example, in June 2025, data from the Human Fertilisation and Embryology Authority (HFEA), a UK-based statutory regulator of fertility treatment, reported that around 52,400 patients underwent over 77,500 IVF cycles at licensed fertility clinics in 2023. Therefore, the increasing prevalence of infertility worldwide is driving the growth of the recurrent implantation failure panels market.
The rise in in vitro fertilization (IVF) and assisted reproductive technology (ART) cycles is also expected to fuel the expansion of the recurrent implantation failure (RIF) panels market over the forecast period. IVF and ART involve medical procedures that support conception by handling eggs, sperm, or embryos outside the body. The growing utilization of these procedures is mainly due to increasing infertility rates, delayed parenthood, and enhanced access to fertility services, motivating more individuals and couples to pursue medical assistance for successful pregnancies. Recurrent implantation failure panels facilitate IVF and ART cycles by identifying genetic, immunological, and molecular factors that may compromise embryo implantation, enabling clinicians to customize treatment approaches and boost pregnancy success rates. For instance, in 2023, according to YourIVFSuccess, an Australia-based government-funded initiative, about 20,417 babies were born via IVF, equating to nearly one in every 16 Australian births resulting from assisted reproductive technologies. Therefore, the growth of IVF and ART cycles is driving the expansion of the recurrent implantation failure panels market.
The development of fertility clinic networks is expected to contribute to the growth of the recurrent implantation failure (RIF) panels market over the forecast period. Fertility clinic networks comprise interconnected centers operating under a coordinated system or brand to provide assisted reproductive services, including IVF. The expansion of these networks is largely fueled by rising patient demand, as networked clinics broaden geographic access, standardize care protocols, and offer more convenient treatment options across regions. Recurrent implantation failure panels support fertility clinic networks by enabling personalized assessment of implantation-related issues, improving treatment success rates, and enhancing patient outcomes across multiple clinical sites. For example, according to YourIVFSuccess, an Australia-based government-funded initiative, more than 112,000 IVF cycles were performed nationwide in 2023, reflecting a 23% increase from 2022. Therefore, the expansion of fertility clinic networks is driving the growth of the recurrent implantation failure panels market.
Major companies operating in the recurrent implantation failure panels market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Illumina Inc., Natera Inc., Redcliffe Labs, MedGenome Labs Ltd., Mayo Clinic Laboratories, Fulgent Genetics Inc., LifeCell International, Kindbody Genetics, MapmyGenome, DNA Labs India, Shree IVF Clinic, Inti Labs, Vida Fertility Genetics, Cleveland Clinic, ReceptivaDx (CicloMed), MatriceLab, Reproductive Genetic Innovations (RGI), BGI Genomics Co. Ltd., Embryolab Next Gen IVF, Aksigen IVF, Progenesis IVF, Vani IVF.
North America was the largest region in the recurrent implantation failure panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recurrent implantation failure panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the recurrent implantation failure panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The recurrent implantation failure panels market consists of sales of blood collection tubes, biopsy instruments, and sample storage vials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Recurrent Implantation Failure Panels Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses recurrent implantation failure panels market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for recurrent implantation failure panels ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recurrent implantation failure panels market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.